Австралія - англійська - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - diclofenac potassium, quantity: 50 mg - oral liquid, powder for - excipient ingredients: potassium bicarbonate; saccharin sodium; mannitol; aspartame; glyceryl behenate; flavour - as short-term treatment (up to one week) for the relief of acute pain states in which there is an inflammatory component. treatment of acute migraine attacks (with or without aura). symptomatic treatment of primary dysmenorrhoea.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

care pharmaceuticals pty ltd - paracetamol, quantity: 24 mg/ml; codeine phosphate hemihydrate, quantity: 1 mg/ml - oral liquid - excipient ingredients: macrogol 400; purified water; saccharin sodium; methyl hydroxybenzoate; glycerol; citric acid monohydrate; sodium citrate dihydrate; propyl hydroxybenzoate; sodium chloride; flavour - for the temporary relief of acute moderate pain when paracetamol alone is not sufficient in patients over the age of 12 years (see also contraindications and paediatric use).

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - oxycodone hydrochloride, quantity: 1 mg/ml - oral liquid, solution - excipient ingredients: saccharin sodium; sodium citrate dihydrate; sodium benzoate; hypromellose; sodium hydroxide; hydrochloric acid; purified water; citric acid monohydrate - oxynorm is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

care pharmaceuticals pty ltd - codeine phosphate hemihydrate, quantity: 1 mg/ml; paracetamol, quantity: 24 mg/ml; promethazine hydrochloride, quantity: 1.3 mg/ml - oral liquid, solution - excipient ingredients: purified water; sodium metabisulfite; sorbitol solution (70 per cent) (non-crystallising); propylene glycol; sucrose; disodium edetate; saccharin sodium; brilliant blue fcf; amaranth; phosphoric acid; ethanol; flavour - for the temporary relief of acute moderate pain when paracetamol alone is not sufficient and sedation is considered beneficial in patients over the age of 12 years ( see also contraindications and paediatric use)

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

clinect pty ltd - chlorpromazine hydrochloride, quantity: 5 mg/ml - oral liquid - excipient ingredients: sucrose; caramel; peppermint oil; spearmint oil; polysorbate 20; purified water; citric acid; sodium citrate dihydrate; ascorbic acid; sodium sulfite; sodium metabisulfite; sodium benzoate; flavour - 1. treatment of acute functional psychosis (eg schizophrenia, mania or psychotic depression). 2. long-term treatment of schizophrenia. 3. short-term treatment of agitation and severe depression. 4. severe behavioural disturbances, as can be found in some children with mental retardation or autism, including the treatment of self-injurious and aggressive behaviour or overactivity. use of chlorpromazine should be in conjunction with an appropriate non-pharmacological management program and long-term use should only be carried out under the supervision of a physician experienced in the management of psychotic disorders in children. 5. in the management of terminal illness to enhance the effect of analgesics and to control nausea and vomiting. 6. control of intractable hiccough.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - prednisolone sodium phosphate, quantity: 6.72 mg/ml (equivalent: prednisolone, qty 5 mg/ml) - oral liquid, solution - excipient ingredients: disodium edetate; dibasic sodium phosphate; propyl hydroxybenzoate; sorbitol solution (70 per cent) (non-crystallising); methyl hydroxybenzoate; purified water; monobasic sodium phosphate; flavour - wherever corticosteroid therapy is indicated.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - dihydrocodeine tartrate, quantity: 1.9 mg/ml - oral liquid - excipient ingredients: purified water; sucrose; citric acid; methyl hydroxybenzoate; amaranth; sorbitol; flavour - for relief of stubborn, unproductive cough.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - cefaclor monohydrate, quantity: 53.72 mg/ml (equivalent: cefaclor, qty 50 mg/ml) - oral liquid, powder for - excipient ingredients: methylcellulose; sodium lauryl sulfate; dimeticone 350; xanthan gum; tapioca starch; erythrosine; sucrose; flavour - aclor is indicated for the treatment of the following types of infections caused by or likely to be caused by susceptible organisms: lower respiratory infections, including pneumonia, bronchitis and exacerbations of chronic bronchitis. upper respiratory tract infections, including pharyngitis, tonsillitis and otitis media. skin and skin structure infections. urinary tract infections including pyelonephritis and cystitis. note: 1. penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. aclor appears to be as effective as phenoxymethyl penicillin in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of aclor in the subsequent prevention of rheumatic fever are not available at present. 2. appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - clavulanic acid, quantity: 11.4 mg/ml; amoxicillin, quantity: 80 mg/ml - oral liquid, powder for - excipient ingredients: silicon dioxide; succinic acid; colloidal anhydrous silica; aspartame; xanthan gum; hypromellose; flavour - augmentin duo 400 oral suspension is indicated in the short term treatment of the following bacterial infections when caused by sensitive organisms (see microbiology). skin and skin structure infections: urinary tract infections (complicated and uncomplicated): upper respiratory tract infections including sinusitis, otitis media: lower respiratory tract infections including acute exacerbations of chronic bronchitis and community acquired pneumonia. appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to augmentin. however, when there is good reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptible studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to augmentin duo 400, should not require the addition of another antibiotic due to the amoxycillin content of augmentin duo 400.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - cefaclor monohydrate, quantity: 26.86 mg/ml (equivalent: cefaclor, qty 25 mg/ml) - oral liquid, powder for - excipient ingredients: methylcellulose; sodium lauryl sulfate; dimeticone 350; xanthan gum; tapioca starch; erythrosine; sucrose; flavour - ceclor is indicated for the treatment of the following types of infections caused by or likely to be caused by susceptible organisms: lower respiratory infections, including pneumonia, bronchitis and exacerbations of chronic bronchitis. upper respiratory tract infections, including pharyngitis, tonsillitis and otitis media. skin and skin structure infections. urinary tract infections including pyelonephritis and cystitis. note: 1. penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. ceclor appears to be as effective as phenoxymethyl penicillin in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of ceclor in the subsequent prevention of rheumatic fever are not available at present. 2. appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor.